Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company’s lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway. The company has license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts. As of July 1, 2025, Inozyme Pharma, Inc. operates as a subsidiary of BioMarin Pharmaceutical Inc..
Metrics to compare | INZY | Peers Peers - average of corresponding metrics from companies closely matching INZY: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipINZYPeersSector |
---|---|---|---|---|
P/E Ratio | −2.4x | 0.0x | −0.5x | |
PEG Ratio | 0.11 | 0.00 | 0.00 | |
Price/Book | 8.2x | 0.0x | 2.6x | |
Price / LTM Sales | - | 0.0x | 3.3x | |
Upside (Analyst Target) | 0.0% | 0.0% | 43.4% | |
Fair Value Upside | Unlock | 0.0% | 7.1% | Unlock |